Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Time to Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped up before the market opened on Tuesday. The stock had previously closed at $9.46, but opened at $9.87. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.47, with a volume of 4,386 shares traded.

Analysts Set New Price Targets

A number of research analysts have recently commented on SGIOY shares. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Three research analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat, the company has an average rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 2.0%

The firm has a market cap of $16.13 billion, a price-to-earnings ratio of 10.53, a price-to-earnings-growth ratio of 3.41 and a beta of 0.10. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $9.24 and a 200-day moving average price of $9.66.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its quarterly earnings data on Thursday, October 29th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.05). Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 37.95% and a return on equity of 14.32%. The firm had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.11 billion. As a group, research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.83 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker. The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.